Abstract
Low-dose valproate semisodium [divalproex sodium, Depakote®; Abbott] may be effective in stabilising symptoms in patients with cyclothymia or bipolar II disorder, according to the findings of a study presented at the 96th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics [San Diego, US; March 1995]. Furthermore, for the first time, researchers have noted a relationship between illness severity and the dosage of valproate semisodium required for symptom stabilisation. The implications of these findings for the treatment of bipolar disorders were discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
